ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Third, to be clinically relevant, I13 exerts an antitumoral effect on imatinib-resistant CML cells, demonstrating that it could be a potential epigenetic drug for the development of a CML therapy that can overcome resistance mediated by the BCR-ABL-T315 mutation.